AEON Biopharma (NASDAQ:AEON), formerly Allied Energy Corp., is a clinical‐stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. The company applies enzyme replacement and gene therapy platforms to address unmet medical needs in central nervous system and metabolic disorders. Its lead program, AES-103, is being developed as an enzyme replacement therapy for Crigler-Najjar syndrome, a hereditary condition characterized by high levels of unconjugated bilirubin.
Beyond AES-103, AEON Biopharma is advancing AES-201 for X-linked adrenoleukodystrophy (X-ALD), a progressive neurological disorder, and AES-104 for post–COVID-19 conditions, commonly referred to as “long COVID.” These programs are in preclinical or early clinical stages, with ongoing efforts to optimize delivery, evaluate safety profiles and establish proof of concept. The company collaborates with academic and research institutions to support its development strategy and accelerate timelines.
Incorporated in Nevada in 1997 and rebranded as AEON Biopharma in late 2020, the company is headquartered in the United States and targets global orphan disease markets. AEON’s leadership team brings extensive experience in biotechnology research, regulatory affairs and commercial planning, positioning the company to advance its pipeline through key development milestones and, ultimately, to market.
Committed to addressing underserved patient populations, AEON Biopharma partners with patient advocacy groups and industry stakeholders to guide its clinical programs. By focusing on innovative approaches to rare diseases, the company aims to build a differentiated portfolio of therapies with the potential to deliver meaningful clinical benefit and improve quality of life for patients worldwide.
